title: [Humanized antibodies as therapeutics].
abstract: Since 1997, nine humanized antibodies received the approval of the FDA to be used as drugs for the treatment of various diseases including transplant rejections, metastatic breast and colon cancers, leukaemia, non-Hodgkin lymphomas, allergic conditions or multiple sclerosis. This review describes techniques used to engineer these antibodies and presents the recent evolutions of these techniques : SDRs grafting or << abbreviated >> CDRs grafting. Based on the illustrative examples of several antibodies, Mylotarg, Herceptin or Xolair, the therapeutic effectiveness of humanized antibodies are underlined and, with the example of Tysabri, the sometimes dramatic adverse effects associated with their clinical use is stressed. In a second part, this review presents some future and realistic avenues to improve the effectiveness of the humanized antibodies, to decrease their immunogenicity and to reduce their cost.
authors.affiliation: UMR 8149 CNRS, IFR 71, Université René Descartes, Paris 5, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, 4, avenue de l'Observatoire, 75006 Paris, France. dominique.bellet@univ-paris5.fr
authors.forename: Dominique
authors.initials: D
authors.lastname: Bellet
authors.forename: Virginie
authors.initials: V
authors.lastname: Dangles-Marie
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001709:Biotechnology / Q000379:methods / Q000639:trends; D005544:Forecasting; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal